Search clinical trials for: STX209

Total 39 results

Seaside Therapeutics, Inc.

Completed

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Terminated

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (Harbor-A)

Fragile X Syndrome

United States
Timothy Roberts
Simons Foundation; Clinical Research Associates, LLC

Completed

MEG Study of Acute STX209 Effects in ASD

Autism Disorder

United States
Seaside Therapeutics, Inc.

Completed

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
UNION therapeutics

Completed

Sensitization Study of ATx201 in Healthy Volunteers

Sensitivity, Contact

United States
UNION therapeutics

Completed

Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo

Impetigo

South Africa
UNION therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis

Canada
UNION therapeutics

Completed

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

Irritation Potential of Topic Agent

United States
Astex Pharmaceuticals, Inc.

Active, not recruiting

Study of ASTX029 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States, Spain, France, United Kingdom
Seaside Therapeutics, Inc.

Suspended

A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome

Fragile X Syndrome

United States
Leadiant Biosciences, Inc.

Completed

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Necrotizing Enterocolitis

United States
Xilio Development, Inc.

Active, not recruiting

XTX202 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Astex Pharmaceuticals, Inc.

Completed

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Healthy Volunteers

United States
Seaside Therapeutics, Inc.
National Institutes of Health (NIH)

Completed

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Fragile X Syndrome

United States
Leadiant Biosciences, Inc.

Completed

Safety and Tolerability of STP206 in Healthy Adult Subjects

Healthy

United States
H. Lee Moffitt Cancer Center and Research Institute
Endo Pharmaceuticals

Completed

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
National Institute of Mental Health (NIMH)

Completed

Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain

mGluR5 Receptors

United States
Endo Pharmaceuticals

Completed

Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) (Bladder Cancer)

Carcinoma in Situ | Bladder Cancer

United States
Sangamo Therapeutics

Active, not recruiting

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients (STEADFAST)

End Stage Renal Disease | Kidney Transplant Rejection

Belgium, Netherlands, United Kingdom
Bayer
Ultragenix pharmaceutical

Active, not recruiting

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

Hemophilia A

Netherlands, United States, Germany, United Kingdom, France, Bulgaria
UNION therapeutics

Completed

Evaluation of ATx201 as a Topical Antibiotic Agent

Infection, Bacterial

Austria
HemaQuest Pharmaceuticals Inc.

Completed

A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Sodium ST20 in Healthy Volunteers

Healthy

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders

Autism Spectrum Disorders

United States
Clinical Research Associates, LLC

Recruiting

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

16P11.2 Deletion Syndrome

United States
King's College London

Completed

Modulation of the Brain Excitatory/Inhibitory (E/I) Balance in Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder

United Kingdom
M.D. Anderson Cancer Center

Not yet recruiting

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Myelodysplastic Neoplasm | Pathway Mutant Myelodysplastic Syndromes

United States
Celso Arango, MD, PhD
UMC Utrecht

Completed

Arbaclofen in Children and Adolescents With ASD (AIMS2-CT1)

Autism Spectrum Disorder

Spain, United Kingdom, France
M.D. Anderson Cancer Center

Suspended

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Boston University
HemaQuest Pharmaceuticals Inc.

Completed

Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon (LB-04-THAL)

Beta Thalassemia Intermedia

Lebanon
Boston University
Mahidol University

Completed

Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand (ST20-P2T)

Beta Thalassemia Intermedia

Thailand
Soligenix
National Cancer Institute (NCI)

Completed

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

Enteritis

United States

3

Subscribe